Title: A Comprehensive Analysis of Percutaneous Liver Biopsy Characteristics and
Pathological Manifestations in a Large Patient Cohort (2009-2024)
Version: 3 Date: 09 Dec 2024
Reviewer:  Speranta Iacob
Reviewer's report:
Major Revision required: The manuscript will be revised for acceptance after addressing the
following points:
1. Discuss the implications of the low Pearson’s correlation coefficients.
2. Acknowledge the absence of FibroScan and CAP measurements as a limitation.
3. Provide a detailed discussion on the biological mechanisms linking EASIX to liver fibrosis
and mortality.
4. Clarify the generalizability of the findings to non-U.S. populations.
5. Expand the discussion on the clinical utility and integration of EASIX into practice.
Title: A Comprehensive Analysis of Percutaneous Liver Biopsy Characteristics and
Pathological Manifestations in a Large Patient Cohort (2009-2024)
Version: 3 Date: 09 Dec 2024
Reviewer:  Speranta Iacob
Reviewer's report:
Major Revision required: The manuscript will be revised for acceptance after addressing the
following points:
1. Discuss the implications of the low Pearson’s correlation coefficients.
2. Acknowledge the absence of FibroScan and CAP measurements as a limitation.
3. Provide a detailed discussion on the biological mechanisms linking EASIX to liver fibrosis
and mortality.
4. Clarify the generalizability of the findings to non-U.S. populations.
5. Expand the discussion on the clinical utility and integration of EASIX into practice.
Please review this paper.
user
Title: A Comprehensive Analysis of Percutaneous Liver Biopsy Characteristics and
Pathological Manifestations in a Large Patient Cohort (2009-2024)
Version: 3 Date: 09 Dec 2024
Reviewer:  Speranta Iacob
Reviewer's report:
Major Revision required: The manuscript will be revised for acceptance after addressing the
following points:
1. Discuss the implications of the low Pearson’s correlation coefficients.
2. Acknowledge the absence of FibroScan and CAP measurements as a limitation.
3. Provide a detailed discussion on the biological mechanisms linking EASIX to liver fibrosis
and mortality.
4. Clarify the generalizability of the findings to non-U.S. populations.
5. Expand the discussion on the clinical utility and integration of EASIX into practice.
assistant